GILEAD - Positioned to Repeat HIV Feat in HCV – Albeit at a High Price!
Gilead (GILD) now has the one of the Best portfolio of Polymerase Inhibitors (PMIs) – PSI-7977 and PSI-938 (PhII/III, HCV), Mericitabine (formerly RG-7128, PhIII, HCV, partnered with Roche) along with its own Protease Inhibitors (PIs, Appendix), and formulating experience to deliver a “single best-in-class IFN-free oral pill”! Like its approach in HIV, we expect GILD to focus on providing drugs to HCV pts with the best dosing, efficacy and safety profile and thus, establish supremacy in the HCV field! In this report, we have analyzed VRUS’ acquisition and its pipeline potencial…. For more detail, please read our report released on 22nd November on GILD titled “Positioned to Repeat HIV Feat in HCV – Albeit at a High Price!”
COMPANIES MENTIONED
GILEAD
GILEAD
